OneCell Diagnostics Secures $16 Million Series A Funding for Global Expansion

OneCell Diagnostics, a pioneer in cancer diagnostics, has raised $16 million in a Series A funding round led by Celesta Capital, with contributions from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.

The funding will accelerate the US expansion of OncoIndx Alfa, the company’s flagship liquid biopsy test. This advanced diagnostic tool identifies circulating tumor cells, enabling precise cancer detection and treatment monitoring.

Founded in 2021, OneCell Diagnostics integrates AI, machine learning, and multi-omics biomarkers with next-generation sequencing to lead the way in precision cancer diagnostics.

“Our mission is to make cancer testing accessible and transformative. This funding strengthens our commitment to improving global cancer care,” said Mohan Uttarwar, CEO and co-founder.

You may also like to read: Airbound Secures $1.7 Million Seed Funding to Transform Drone Logistics

The company has tested its groundbreaking technology on nearly 10,000 patients in India and collaborates with renowned institutions like AIIMS New Delhi, Tata Memorial Centre, and academic leaders like Harvard Medical School and Stanford University.

With this funding, OneCell Diagnostics is set to redefine cancer care by advancing its innovative solutions for monitoring treatment, tracking disease progression, and detecting recurrence.